Pancreatitis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, “Pancreatitis Therapeutics Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Pancreatitis Therapeutics market. The report identifies the key trends shaping and driving the global Pancreatitis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Pancreatitis Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Pancreatitis Therapeutics market. Its scope includes -

• Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Pancreatitis Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
• Analysis of the current and future competition in the seven key countries Pancreatitis Therapeutics market.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Pancreatitis Therapeutics market.
• Analysis of key recent licensing and partnership agreements in Pancreatitis Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global Pancreatitis Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Pancreatitis Therapeutics market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global Pancreatitis Therapeutics market landscape? – Identify, understand and capitalize.

Table of Contents

1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 5

2 Pancreatitis Therapeutics Introduction 6
2.1 Overview 6
2.2 Classification of Pancreatitis 6
2.3 Epidemiology 7
2.4 Etiology 8
2.5 Pathophysiology 8
2.6 Signs and Symptoms 8
2.7 Complications 8
2.8 Diagnosis 9
2.8.1 Physical Examination 9
2.8.2 Stool Tests 9
2.8.3 Blood Tests 10
2.8.4 Imaging Tests 10
2.9 Treatment 12
2.9.1 Alcohol Avoidance 12
2.9.2 Hospitalization 12
2.9.3 Surgery 12
2.10 GlobalData Pipeline Report Guidance 13

3 Pancreatitis Therapeutics - Market Characterization 14
3.1 Pancreatitis Therapeutics Market Size (2006-2011) - Global 14
3.2 Pancreatitis Therapeutics Market Forecast (2011-2019) - Global 16
3.3 Pancreatitis Therapeutics Market Size (2006-2011) - US 18
3.4 Pancreatitis Therapeutics Market Forecast (2011-2019) - The US 19
3.5 Pancreatitis Therapeutics Market Size (2006-2011) - The UK 20
3.6 Pancreatitis Therapeutics Market Forecast (2011-2019) - The UK 21
3.7 Pancreatitis Therapeutics Market Size (2006-2011) - France 22
3.8 Pancreatitis Therapeutics Market Forecast (2011-2019)- France 23
3.9 Pancreatitis Therapeutics Market Size (2006-2011) - Germany 24
3.10 Pancreatitis Therapeutics Market Forecast (2011-2019) - Germany 25
3.11 Pancreatitis Therapeutics Market Size (2006-2011) - Italy 26
3.12 Pancreatitis Therapeutics Market Forecast (2011-2019) - Italy 27
3.13 Pancreatitis Therapeutics Market Size (2006-2011) - Spain 28
3.14 Pancreatitis Therapeutics Market Forecast (2011-2019) - Spain 29
3.15 Pancreatitis Therapeutics Market Size (2006-2011) - Japan 30
3.16 Pancreatitis Therapeutics Market Forecast (2011-2019) - Japan 31
3.17 Drivers and Barriers for the Pancreatitis Therapeutics Market 32
3.17.1 Drivers for the Pancreatitis Therapeutics Market 32
3.17.2 Barriers to the Pancreatitis Therapeutics Market 32
3.18 .Key Events Impacting the Future Market 32
3.18.1 Opportunity and Unmet Need 32
3.19 Key Takeaway 33

4 Pancreatitis Therapeutics Market - Competitive Assessment 34
4.1 Overview 34
4.1.1 Strategic Competitor Assessment 34
4.2 Profiles of the Commonly Used Products in the Pancreatitis Therapeutics Market 35
4.2.1 Pancrelipase (Zenpep, Creon, Pancreaze) 35
4.2.2 Non-steroidal Anti-inflammatory Drugs 35
4.2.3 Opioids 36
4.2.4 Antibiotics 37
4.2.5 Tricyclic Antidepressants 37
4.3 Key Takeaway 37

5 Pancreatitis Therapeutics Market - Pipeline Assessment 38
5.1 Overview 38
5.2 Strategic Pipeline Assessment 38
5.3 Pancreatitis Pipeline Analysis - Pipeline by Clinical Phases of Development 38
5.3.1 Pancreatitis Therapeutics – Phase III Pipeline 38
5.3.2 Pancreatitis Therapeutics – Phase II/III Pipeline 39
5.3.3 Pancreatitis Therapeutics – Phase II Pipeline 39
5.3.4 Pancreatitis Therapeutics – Phase I/II Pipeline 39
5.3.5 Pancreatitis Therapeutics – Phase I Pipeline 39
5.3.6 Pancreatitis Therapeutics – Preclinical Pipeline 39
5.4 Pancreatitis Pipeline by Mechanism of Action 40
5.5 Pancreatitis Technology Trends Analytical Framework 41
5.6 Molecule Profile for Key Drugs under Clinical Development 41
5.6.1 Namisol 41
5.7 Key Takeaway 41

6 Pancreatitis Therapeutics - Clinical Trials Mapping 42
6.1 Clinical Trials by Country (The US, EU5 and Japan) 42
6.2 Clinical Trials Mapping by Phase 43
6.3 Clinical Trials Mapping by Trial Status 44
6.4 Overall Sponsors 45
6.5 Prominent Sponsors 46
6.6 Top Companies Participating in Pancreatitis Therapeutics Clinical Trials 47

7 Pancreatitis Therapeutics: Strategic Assessment 48
7.1 Future Market Competition Scenario 48

8 Pancreatitis Therapeutics: Future Players in the Market 49
8.1 Introduction 49
8.2 Company Profiles 50
8.2.1 Echo Pharmaceuticals 50

9 Pancreatitis Therapeutics: Licensing and Partnership Deals 51

10 Pancreatitis Therapeutics - Appendix 52
10.1 Definitions 52
10.2 Acronyms 52
10.3 Methodology 53
10.3.1 Coverage 53
10.3.2 Secondary Research 53
10.3.3 Forecasting 53
10.3.4 Primary Research 55
10.3.5 Expert Panel Validation 56
10.4 Contact Us 56
10.5 Disclaimer 56
10.6 Bibliography 56

List of Tables

Table 1: Historical Prevalence of Pancreatitis for Seven Major Markets 7
Table 2: Forecasted Prevalence of Pancreatitis for Seven Major Markets 8
Table 3: Pancreatitis Therapeutics Market, Global, Revenue ($m), 2006–2011 14
Table 4: Pancreatitis Therapeutics Market, Global, Forecast ($m), 2011–2019 16
Table 5: Pancreatitis Therapeutics Market, The US, Revenue ($m), 2006–2011 18
Table 6: Pancreatitis Therapeutics Market, The US, Revenue ($m), 2011–2019 19
Table 7: Pancreatitis Therapeutics Market, The UK, Revenue ($m), 2006–2011 20
Table 8: Pancreatitis Therapeutics Market, The UK, Forecast ($m), 2011–2019 21
Table 9: Pancreatitis Therapeutics Market, France, Revenue ($m), 2006–2011 22
Table 10: Pancreatitis Therapeutics Market, France, Forecast ($m), 2011–2019 23
Table 11: Pancreatitis Therapeutics Market, Germany, Revenue ($m), 2006–2011 24
Table 12: Pancreatitis Therapeutics Market, Germany, Forecast ($m), 2011–2019 25
Table 13: Pancreatitis Therapeutics Market, Italy, Revenue ($m), 2006–2011 26
Table 14: Pancreatitis Therapeutics Market, Italy, Forecast ($m), 2011–2019 27
Table 15: Pancreatitis Therapeutics Market, Spain, Revenue ($m), 2006–2011 28
Table 16: Pancreatitis Therapeutics Market, Spain, Forecast ($m), 2011–2019 29
Table 17: Pancreatitis Therapeutics Market, Japan, Revenue ($m), 2006–2011 30
Table 18: Pancreatitis Therapeutics Market, Japan, Forecast ($m), 2011–2019 31
Table 19: Pancreatitis Therapeutics – Phase III Pipeline 38
Table 20: Pancreatitis Therapeutics – Phase II/III Pipeline 39
Table 21: Pancreatitis Therapeutics – Phase II Pipeline 39
Table 22: Pancreatitis Therapeutics – Phase I/II Pipeline 39
Table 23: Pancreatitis Therapeutics – Phase I Pipeline 39
Table 24: Pancreatitis Therapeutics – Preclinical Pipeline 39
Table 25: Pancreatitis Therapeutics – Discovery Pipeline 39
Table 26: Pancreatitis Therapeutics – Clinical Trials by Country, 2012 42
Table 27: Pancreatitis Therapeutics – Clinical Trials by Phase, 2012 43
Table 28: Pancreatitis Therapeutics – Clinical Trials by Status, 2012 44
Table 29: Pancreatitis Therapeutics – Clinical Trials by Overall Sponsors, 2012 45
Table 30: Pancreatitis Therapeutics – Clinical Trials by Prominent Sponsors, 2012 46
Table 31: Pancreatitis Therapeutics Clinical Trial – Company Sponsors by Phase, 2012 47
Table 32: Echo Pharmaceuticals – Pancreatitis Pipeline 50
Table 33: Licensing and Partnership Deals 51

List of Figures

Figure 1: Classification of Pancreatitis 6
Figure 2: Patient Share of Pancreatitis in the Seven Major Markets, 2011 7
Figure 3: Tests Used for the Diagnosis of Pancreatitis 9
Figure 4: Computerized Tomography Scan 11
Figure 5: Pancreatitis Therapeutics Market, Global, Revenue ($m), 2006–2011 14
Figure 6: Pancreatitis Therapeutics, Market Share ($m), 2011 15
Figure 7: Pancreatitis Therapeutics Market, Global, Forecast ($m), 2011–2019 16
Figure 8: Pancreatitis Therapeutics, Market Share ($m), 2019 17
Figure 9: Pancreatitis Therapeutics Market, The US, Revenue ($m), 2006–2011 18
Figure 10: Pancreatitis Therapeutics Market, The US, Forecast ($m), 2011–2019 19
Figure 11: Pancreatitis Therapeutics Market, The UK, Revenue ($m), 2006–2011 20
Figure 12: Pancreatitis Therapeutics Market, The UK, Forecast ($m), 2011–2019 21
Figure 13: Pancreatitis Therapeutics Market, France, Revenue ($m), 2006–2011 22
Figure 14: Pancreatitis Therapeutics Market, France, Forecast ($m), 2011–2019 23
Figure 15: Pancreatitis Therapeutics Market, Germany, Revenue ($m), 2006–2011 24
Figure 16: Pancreatitis Therapeutics Market, Germany, Forecast ($m), 2011–2019 25
Figure 17: Pancreatitis Therapeutics Market, Italy, Revenue ($m), 2006–2011 26
Figure 18: Pancreatitis Therapeutics Market, Italy, Forecast ($m), 2011–2019 27
Figure 19: Pancreatitis Therapeutics Market, Spain, Revenue ($m), 2006–2011 28
Figure 20: Pancreatitis Therapeutics Market, Spain, Forecast ($m), 2011–2019 29
Figure 21: Pancreatitis Therapeutics Market, Japan, Revenue ($m), 2006–2011 30
Figure 22: Pancreatitis Therapeutics Market, Japan, Forecast ($m), 2011–2019 31
Figure 23: Pancreatitis Therapeutics, Key Events Impacting the Future Market, 2012 32
Figure 24: Opportunity and Unmet Need in the Pancreatitis Therapeutics Market, 2012 33
Figure 25: Pancreatitis Therapeutics Market - Strategic Competitor Assessment, 2012 35
Figure 26: Pancreatitis Therapeutics - Pipeline by Phase of Clinical Development, 2012 38
Figure 27: Pancreatitis Therapeutics – Clinical Pipeline by Mechanism of Action, 2012 40
Figure 28: Pancreatitis Therapeutics - Technology Trends Analytical Framework, 2012 41
Figure 29: Pancreatitis Therapeutics – Clinical Trials by Country, 2012 42
Figure 30: Pancreatitis Therapeutics – Clinical Trials by Phase, 2012 43
Figure 31: Pancreatitis Therapeutics – Clinical Trials by Status, 2012 44
Figure 32: Pancreatitis Therapeutics – Clinical Trials by Overall Sponsors, 2012 45
Figure 33: Pancreatitis Therapeutics – Clinical Trials by Prominent Sponsors, 2012 46
Figure 34: Pancreatitis Therapeutics Clinical Trial – Company Sponsors by Phase, 2012 47
Figure 35: Pancreatitis Therapeutics, Strategic Assessment, 2012 48
Figure 36: Pancreatitis Therapeutics Market – Clinical Pipeline by Company, 2012 49
Figure 37: GlobalData Market Forecasting Model 55